Compare Stocks: IMAB, MAZE, QURE, and RARE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMAB I-Mab	$4.76 +2.5%	$4.76	$0.81 ▼ $6.79	$388.29M	1.45	1.61 million shs	1.51 million shs
MAZE Maze Therapeutics	$27.48 +4.8%	$26.78	$21.95 ▼ $53.65	$1.46B	2.16	977,360 shs	539,300 shs
QURE uniQure	$22.52 +7.4%	$39.75	$8.73 ▼ $71.50	$1.45B	1.06	3.72 million shs	1.61 million shs
RARE Ultragenyx Pharmaceutical	$15.17 +1.8%	$19.05	$12.73 ▼ $39.89	$1.47B	0.35	5.41 million shs	3.33 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMAB I-Mab	0.00%	0.00%	0.00%	0.00%	-22.43%
MAZE Maze Therapeutics	+4.77%	+6.18%	+13.41%	-2.28%	-6.08%
QURE uniQure	+7.39%	-0.09%	-47.75%	-44.05%	-64.16%
RARE Ultragenyx Pharmaceutical	+1.81%	-0.78%	+16.07%	-48.19%	-54.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMAB I-Mab	$4.76 +2.5%	$4.76	$0.81 ▼ $6.79	$388.29M	1.45	1.61 million shs	1.51 million shs
MAZE Maze Therapeutics	$27.48 +4.8%	$26.78	$21.95 ▼ $53.65	$1.46B	2.16	977,360 shs	539,300 shs
QURE uniQure	$22.52 +7.4%	$39.75	$8.73 ▼ $71.50	$1.45B	1.06	3.72 million shs	1.61 million shs
RARE Ultragenyx Pharmaceutical	$15.17 +1.8%	$19.05	$12.73 ▼ $39.89	$1.47B	0.35	5.41 million shs	3.33 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMAB I-Mab	0.00%	0.00%	0.00%	0.00%	-22.43%
MAZE Maze Therapeutics	+4.77%	+6.18%	+13.41%	-2.28%	-6.08%
QURE uniQure	+7.39%	-0.09%	-47.75%	-44.05%	-64.16%
RARE Ultragenyx Pharmaceutical	+1.81%	-0.78%	+16.07%	-48.19%	-54.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMAB I-Mab	2.60	Moderate Buy	$7.33	54.22% Upside
MAZE Maze Therapeutics	3.08	Buy	$63.40	130.71% Upside
QURE uniQure	2.76	Moderate Buy	$53.25	136.46% Upside
RARE Ultragenyx Pharmaceutical	2.45	Hold	$33.65	121.82% Upside

Current Analyst Ratings Breakdown

Latest IMAB, MAZE, QURE, and RARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	QURE uniQure	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$27.00 ➝ $48.00
10/15/2026	RARE Ultragenyx Pharmaceutical	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$16.00
10/6/2026	RARE Ultragenyx Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/5/2026	QURE uniQure	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Overweight ➝ Equal Weight	$60.00 ➝ $28.00
10/2/2026	QURE uniQure	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$65.00 ➝ $48.00
9/30/2026	QURE uniQure	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$46.00 ➝ $31.00
9/29/2026	QURE uniQure	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$75.00
9/29/2026	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$110.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$50.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMAB I-Mab	N/A	N/A	N/A	N/A	$2.47 per share	N/A
MAZE Maze Therapeutics	$167.50M	9.11	N/A	N/A	$7.38 per share	3.72
QURE uniQure	$16.10M	97.03	N/A	N/A	$3.19 per share	7.06
RARE Ultragenyx Pharmaceutical	$673M	2.22	N/A	N/A	($0.83) per share	-18.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMAB I-Mab	-$22.23M	-$0.36	N/A	N/A	N/A	N/A	-19.65%	-18.58%	N/A
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	N/A	-44.40%	11/3/2026 (Estimated)

Latest IMAB, MAZE, QURE, and RARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	QURE uniQure	-$0.9154	N/A	N/A	N/A	$6.21 million	N/A
11/3/2026	Q3 2026	RARE Ultragenyx Pharmaceutical	-$1.11	N/A	N/A	N/A	$182.19 million	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMAB I-Mab	N/A	22.82	22.82
MAZE Maze Therapeutics	0.09	18.31	18.31
QURE uniQure	0.15	10.01	10.01
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMAB I-Mab	38.38%
MAZE Maze Therapeutics	N/A
QURE uniQure	78.83%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
IMAB I-Mab	22.10%
MAZE Maze Therapeutics	5.30%
QURE uniQure	4.65%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
MAZE Maze Therapeutics	141	55.55 million	52.61 million	N/A
QURE uniQure	221	69.37 million	66.14 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

IMAB, MAZE, QURE, and RARE Headlines

Recent News About These Companies

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

October 15 at 11:35 AM | zacks.com

UBS Group Begins Coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE)

October 15 at 9:05 AM | marketbeat.com

Ultragenyx makes swift $413M return on FDA review vouchers after summer of gene therapy nods

October 15 at 2:04 AM | fiercepharma.comF

Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203M

October 14 at 4:03 PM | marketwatch.com

Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher for $203 Million

October 14 at 4:03 PM | finance.yahoo.com

Ultragenyx To Sell Rare Pediatric Disease Priority Review Voucher For $203 Mln

October 14 at 4:03 PM | rttnews.com

Ultragenyx to sell Fayuvi FDA priority review voucher for $203M

October 14 at 4:03 PM | seekingalpha.com

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

October 14 at 11:31 AM | zacks.com

Ultragenyx Sells FDA Priority Review Voucher for Cash

October 14 at 9:31 AM | tipranks.com

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

October 14 at 8:30 AM | globenewswire.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr.

October 14 at 2:00 AM | marketbeat.com

Ultragenyx Pharmaceutical (RARE) Receives a Hold from RBC Capital

October 10, 2026 | theglobeandmail.com

Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher

October 8, 2026 | pharmexec.comP

Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?

October 8, 2026 | finance.yahoo.com

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

October 8, 2026 | zacks.com

Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

October 7, 2026 | marketscreener.comM

Ultragenyx To Sell Rare Pediatric Disease Voucher For $210 Mln

October 7, 2026 | rttnews.com

Ultragenyx lands $210M deal to sell FDA priority review voucher – Retail sees 'huge' buying opportunity

October 7, 2026 | msn.com

Ultragenyx to sell FDA priority review voucher for $210M

October 7, 2026 | seekingalpha.com

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

October 7, 2026 | proactiveinvestors.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9% - Here's Why

October 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMAB, MAZE, QURE, and RARE Company Descriptions

I-Mab NASDAQ:IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Maze Therapeutics NASDAQ:MAZE

$27.48 +1.25 (+4.77%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$27.15 -0.33 (-1.20%)

As of 10/15/2026 07:30 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

uniQure NASDAQ:QURE

$22.52 +1.55 (+7.39%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$22.71 +0.19 (+0.86%)

As of 04:19 AM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Ultragenyx Pharmaceutical NASDAQ:RARE

$15.17 +0.27 (+1.81%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$15.25 +0.08 (+0.53%)

As of 04:02 AM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMAB, MAZE, QURE, and RARE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMAB, MAZE, QURE, and RARE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMAB, MAZE, QURE, and RARE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMAB, MAZE, QURE, and RARE Company Descriptions

I-Mab NASDAQ:IMAB

Maze Therapeutics NASDAQ:MAZE

uniQure NASDAQ:QURE

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMAB, MAZE, QURE, and RARE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMAB, MAZE, QURE, and RARE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMAB, MAZE, QURE, and RARE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMAB, MAZE, QURE, and RARE Company Descriptions

I-Mab NASDAQ:IMAB

Maze Therapeutics NASDAQ:MAZE

uniQure NASDAQ:QURE

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools